Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 1996

View Archived Issues

Sanofi reports tachykinin antagonists

SNX-111 development re-scheduled

Roche Bioscience-Signal drug discovery collaboration

Zambon product pipeline in review

Antiacne combination now available in Canada

Ciba-Geigy advances wound-healing agent into phase II

Topical clotrimazole for the treatment of actinic keratosis

Generic cefaclor approved in the U.S.

Takeda develops new pediatric formulation of Firstcin

Bayer claims naphthyridine derivatives

Takeda discloses anti-Ureaplasma agents

U.S. and Canadian researchers report fungicidal conjugated styryl ketones

Novel antifungal antibiotic reported by German and Swedish researchers

Positive phase III results with AmBisome to be included in NDA filing

High clinical efficacy reported for Penederm's Mentax antifungal product

Lilly's newest antipicornavirus agents

Topical Reticulose reported to be effective against HPV

Efficacy and safety of antisense compound for CMV retinitis confirmed

New antiinfluenza virus agent reported by Gilead Sciences

Anti-HIV research continues at Boehringer Ingelheim

Anti-HIV bicyclic phosphoramides from DuPont Merck

Novel class of HIV protease inhibitors with improved activity

Ciba characterizes another novel HIV protease inhibitor

U.K. introduction for lamivudine

Animal and human results presented on Aronex's lead anti-HIV integrase inhibitor

A novel mechanism for inhibiting HIV infection using fibronectin fragments

Anti-HIV agents reported by Japanese researchers

Clinical results with VIMRxyn in AIDS

Remune phase II trial interim results

Procept to develop vaginal gel for the prevention of HIV in women

Sequus signs international marketing agreement for Caelyx/Doxil

New launch for dronabinol in AIDS and cancer patients

Immunization with HIV-1 Tat protein as a strategy for AIDS vaccination

CMV protease structure reported by three different pharmaceutical companies

Sankyo discloses anthelmintic agents

U.S. patent covers hemopoietic regulator with potential in rheumatoid arthritis

Anika receives European marketing approval for osteoarthritis product

Development of COX-2 inhibitors at Searle

Meloxicam launched in Great Britain

TAK-603 in clinical development for arthritis

Kureha glycoproteins show antitumor and immunomodulatory effects

Immunosuppressant oligopeptide from Italfarmaco

Clinical trial of an oral Campylobacter vaccine and adjuvant combination

Promising phase II results with vaccine for staph infections

Joint venture to develop Biopharmaceutics' orphan anticancer drug

First localized treatment for fatal brain cancer approved by the FDA

Prostate cancer treatment approved by the FDA

Cel-Sci's Multikine to be tested clinically at additional centers

Mitsubishi reports isolation of PI 3-kinase inhibitors

Japanese researchers report new antiangiogenic compound

Antitumor lipid peroxidation inhibitor from Kirin Brewery

ET-743 product overview and development update

Clinical trial of gene therapy for malignant brain tumors

Antisense compound displays activity in animal models of human cancer

Clinical benefits of p53 gene therapy

Promising preclinical and clinical results for Genta's lead antisense compound

Takeda's anticancer drug pipeline reviewed

Anticataract and NGF production-enhancing compounds

Kyowa Hakko describes protein inducing osteoblast proliferation

Nippon Shoji's newest ACAT inhibitors

Takeda reports new agent for improving lipid metabolism

Hypocholesterolemic and hypocholesterolemic/antioxidant compounds from Pierre Fabre

Lilly's antiobesity proteins

Tularik-Japan Tobacco leptin gene collaboration

Orphan drug finally approved for urea cycle disorders

Takeda's pipeline of metabolic drugs

Novel MAb reported by Kyowa Hakko

Neoprobe enters into marketing agreement with U.S. Surgical for surgical cancer detection products

First and only breath test for the diagnosis of H. pylori infection approved in the U.S.

Xytronyx files PMA for periodontitis diagnosis and monitoring test

Albunex dispute settled

Egis claims new anxiolytics with a favorable side effect profile

New anxiolytic from SmithKline Beecham

Approval sought for antidepressant from Pharmacia & Upjohn

Patent coverage for combinatorial chemistry approach licensed to Houghten

New high-throughput screening technology from Axiom accelerates drug discovery

BTG licenses gene delivery technology to GenVec

Aston acquired by Oncogene Science

Genzyme to acquire Neozyme II

Synthelabo strengthens its presence in Germany and acquires new technological expertise

Approval for controlled-release carbamazepine tablets

Inhibitors of neuronal NO may halt neuronal degeneration in Parkinson's disease

Advisory committee deems MS treatment safe and effective

Cell Therapeutics awarded research grant for MS

Rilutek now available for ALS patients in the U.K.

Novel antiemetic/gastric prokinetic agent from Dainippon

Neurite outgrowth inducers presented by Kitasato Institute

Natural cerebral function-improving agents from Yamanouchi

Sagami prepares NGF production-enhancing compounds

Yamanouchi describes AMPA antagonists for stroke

Glaxo Wellcome prepares a novel class of glycine-site NMDA receptor antagonists

Takeda's CNS pipeline updated

New hay fever remedy available for the fall allergy season

New cough/cold remedy introduced in the U.S.

E. Merck reports PDE IV inhibitors

Quinoline LTD4/LTE4 inhibitors from Ciba-Geigy

Orally bioavailable LTD4 antagonists from Menarini

Researchers recommend use of inhaled beta-agonists on an as-needed basis in mild asthma

Bristol-Myers Squibb continues to search for new ET antagonists

Mitsui's Na+/H+-exchange inhibitors for cardiovascular disorders

Dual ACE/NEP inhibitors from ADIR

Improved dopaminergic agents from Zambon for cardiovascular disorders

Novel free radical scavengers reported by Merrell

Bayer investigates agents for arteriosclerosis, restenosis

Tyrosine kinase inhibitors from Warner-Lambert

Cypros seeks broad international patent coverage for CPC-111

Hoechst claims new antiarrhythmic agents

Hoechst investigates Na+/H+-exchange inhibitors

Japanese and Korean researchers report improved antiarrhythmic agents

Yamanouchi launches treatment for heart failure

New treatment for peripheral vascular diseases cleared for clinical trials in the U.K.

Cardiovascular R&D at Takeda

Thrombin inhibitors with improved selectivity from Servier

DuPont Merck proposes new standards for warfarin products

gpIIb/IIIa antagonist selected for clinical evaluation at DuPont Merck

Tanabe reports t-PA-enhancing compounds

Gensia and Microbix agreement for generic urokinase alternative

Yamanouchi reports agent for urinary incontinence

Generic dicyclomine HCl now available in the U.S.

p65 antisense oligonucleotides for Crohn's disease

Prokinetic agents from Nisshin Flour Milling

First combined hepatitis A/B vaccine approved

GI drugs under development at Takeda

Antihyperglycemic agents from Wyeth-Ayerst

Aldose reductase inhibitors from Dainippon

U.S. clinical trials on nonsurgical alternative to hysterectomy ahead of schedule

Endocrine drugs in development at Takeda

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...